Johnson & Johnson (NYSE:JNJ) Rating Reiterated by UBS AG

Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reiterated by stock analysts at UBS AG in a report issued on Wednesday, July 19th, The Fly reports. They presently have a $148.00 target price on the stock, up from their previous target price of $136.00. UBS AG’s target price would suggest a potential upside of 11.19% from the stock’s current price.

Other research analysts have also issued reports about the company. Cowen and Company reaffirmed a “buy” rating and issued a $143.00 target price (up from $138.00) on shares of Johnson & Johnson in a research report on Friday, May 19th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 target price on the stock in a research report on Thursday, May 18th. BMO Capital Markets reaffirmed a “buy” rating and issued a $132.00 target price on shares of Johnson & Johnson in a research report on Friday, June 2nd. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $128.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 15th. Finally, BidaskClub lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $133.72.

Shares of Johnson & Johnson (JNJ) traded up 0.01% during midday trading on Wednesday, hitting $133.10. The stock had a trading volume of 4,270,571 shares. The stock has a 50-day moving average price of $133.09 and a 200-day moving average price of $126.30. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The stock has a market cap of $357.24 billion, a P/E ratio of 22.52 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the company posted $1.74 EPS. Equities analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (NYSE:JNJ) Rating Reiterated by UBS AG” was published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/13/johnson-johnson-nysejnj-receives-buy-rating-from-ubs-ag-updated-updated-updated.html.

In related news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of the stock. Amtrust Financial Services Inc. bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $1,151,000. CWA Asset Management Group LLC increased its position in shares of Johnson & Johnson by 13.1% in the fourth quarter. CWA Asset Management Group LLC now owns 55,685 shares of the company’s stock worth $6,415,000 after buying an additional 6,451 shares during the last quarter. Capital Analysts LLC increased its position in shares of Johnson & Johnson by 6.6% in the fourth quarter. Capital Analysts LLC now owns 24,731 shares of the company’s stock worth $2,849,000 after buying an additional 1,522 shares during the last quarter. RBO & Co. LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $24,734,000. Finally, Glenview Trust Co bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $18,192,000. Institutional investors own 66.06% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

The Fly

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply